Subgroup analyses of randomized clinical trials showed a trend to benefit of schemes with three versus two active drugs. 6 , 11 , 12 , 19 In addition, published non-randomized trial and observational studies with three active drugs reported very high rates of virologic suppression. 13 , 14 , 15 In our exploratory analysis, differences in the proportion of patients with viral load <50 copies/mL among patients with three or two full active drugs were not observed.
← all excerpts
High rate of virologic suppression with darunavir/ritonavir plus optimized background therapy among highly antiretroviral-experienced HIV-infected patients: results of a prospective cohort study in São Paulo, Brazil.
1
—
—